PL429672A1 - Preparat zawierający ksantohumol i zastosowanie ksantohumolu - Google Patents

Preparat zawierający ksantohumol i zastosowanie ksantohumolu

Info

Publication number
PL429672A1
PL429672A1 PL429672A PL42967219A PL429672A1 PL 429672 A1 PL429672 A1 PL 429672A1 PL 429672 A PL429672 A PL 429672A PL 42967219 A PL42967219 A PL 42967219A PL 429672 A1 PL429672 A1 PL 429672A1
Authority
PL
Poland
Prior art keywords
xanthohumol
preparation containing
chemotherapy
mammal
prevention
Prior art date
Application number
PL429672A
Other languages
English (en)
Inventor
Paweł ZAJDEL
Łukasz PAWEŁEK
Original Assignee
Bioxan Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioxan Spółka Z Ograniczoną Odpowiedzialnością filed Critical Bioxan Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL429672A priority Critical patent/PL429672A1/pl
Priority to PCT/IB2020/053577 priority patent/WO2020212882A1/en
Publication of PL429672A1 publication Critical patent/PL429672A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Przedmiotem, zgłoszenia jest preparat zawierający jako substancję czynną ksantohumol lub jego farmaceutycznie dopuszczalną sól lub kompleks ksantohumolu z metalem do stosowania w leczeniu lub zapobieganiu powikłaniom kardiologicznym towarzyszącym chemioterapii u ssaka. Zgłoszenie zawiera też zastosowanie ksantohumolu lub jego farmaceutycznie dopuszczalnej soli lub kompleksu ksantohumolu z metalem w leczeniu lub zapobieganiu powikłaniom kardiologicznym towarzyszącym chemioterapii u ssaka.
PL429672A 2019-04-17 2019-04-17 Preparat zawierający ksantohumol i zastosowanie ksantohumolu PL429672A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL429672A PL429672A1 (pl) 2019-04-17 2019-04-17 Preparat zawierający ksantohumol i zastosowanie ksantohumolu
PCT/IB2020/053577 WO2020212882A1 (en) 2019-04-17 2020-04-16 A preparation comprising xanthohumol and use of xanthohumol

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL429672A PL429672A1 (pl) 2019-04-17 2019-04-17 Preparat zawierający ksantohumol i zastosowanie ksantohumolu

Publications (1)

Publication Number Publication Date
PL429672A1 true PL429672A1 (pl) 2020-10-19

Family

ID=71092563

Family Applications (1)

Application Number Title Priority Date Filing Date
PL429672A PL429672A1 (pl) 2019-04-17 2019-04-17 Preparat zawierający ksantohumol i zastosowanie ksantohumolu

Country Status (2)

Country Link
PL (1) PL429672A1 (pl)
WO (1) WO2020212882A1 (pl)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2249641B1 (en) * 2008-02-27 2016-01-06 Flaxan GmbH & Co. KG Novel compositions containing xanthohumol-cyclodextrin complexes
DE102009015917A1 (de) * 2009-03-13 2010-10-14 Lang, Florian, Prof. Dr. Mittel zur Hemmung und/oder Prophylaxe von Eryptose
KR20140032343A (ko) * 2010-10-10 2014-03-14 에릭 쿠르츠 홍조 부작용이 감소된 니아신 제제 및 방법들
JP6668073B2 (ja) * 2012-07-26 2020-03-18 アントニオ・アルカイニＡｎｔｏｎｉｏ Ａｒｃａｉｎｉ 焙煎抽出物およびキサントフモールを含む組成物の使用
ES2763372T3 (es) * 2014-11-11 2020-05-28 Ernst Rainer Weissenbacher Composición que comprende un acidificante, harina de cereales y lúpulo
MX2021009540A (es) * 2016-02-04 2022-12-14 Auransa Inc Composiciones farmaceuticas y metodos para contrarrestar la cardiotoxicidad inducida por quimioterapia.
US9980925B2 (en) * 2016-04-25 2018-05-29 University Of South Carolina Xanthohumol in antiarrythmic applications
PL235226B1 (pl) * 2016-10-12 2020-06-15 Bioactive Tech Spolka Z Ograniczona Odpowiedzialnoscia Ksantohumol do zastosowania w leczeniu lub zapobieganiu i profilaktyce chorób hemoroidalnych oraz kompozycja zawierająca ksantohumol
US11224558B2 (en) * 2017-04-13 2022-01-18 Jean Paul Remon Xanthohumol-based compositions

Also Published As

Publication number Publication date
WO2020212882A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
CA3148745A1 (en) Kras g12d inhibitors
MX2020013557A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo.
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
MX2018010788A (es) Composicion oftalmologica.
MX370099B (es) Combinación que comprende un inhibidor de fgfr y un inhibidor de cmet para el tratamiento del cáncer.
WO2017091739A8 (en) Topical film-forming spray
WO2017037594A3 (zh) 用于减少局部脂肪的医药组成物及其用途
MX2017007178A (es) Formulaciones liquidas estables de virus de vacuna.
PH12019550263A1 (en) A Pharmaceutical Composition for Anaemia
MX2020005942A (es) Delgada pelicula oral con alta carga de agente activo.
PH12017502376B1 (en) Oral solid formulation containing irinotecan and method of preparing the same
MX2017009600A (es) Derivados de 2-fenil-3h-imidazo[4,5-b]piridina utiles como inhibidores de actividad de receptor huerfano similar a tirosina cinasa (ror1) de tirosina cinasa de mamifero.
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
WO2019108021A3 (ko) 토파시티닙을 포함하는 약제학적 조성물
MX2018012800A (es) Administracion de metabolitos de berberina.
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
EA201890896A1 (ru) Твердый препарат для перорального применения, содержащий аморфный солифенацин, и способ его получения
PH12019500919A1 (en) Esomeprazole~containing complex capsule and preparation method therefor
PL429672A1 (pl) Preparat zawierający ksantohumol i zastosowanie ksantohumolu
EP3898582A4 (en) NEW SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF
EP3867222A4 (en) GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF
WO2019115493A3 (en) C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain
ZA202200331B (en) Naltrexone formulation
PL419082A1 (pl) Ksantohumol do zastosowania w leczeniu lub zapobieganiu i profilaktyce chorób hemoroidalnych oraz kompozycja zawierająca ksantohumol